[{"orgOrder":0,"company":"Osaka University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase IV","graph3":"Osaka University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Osaka University \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Osaka University \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ SHIRE PLC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ SHIRE PLC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Salem Veterans Affairs Medical Center","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Salem Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Salem Veterans Affairs Medical Center \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Salem Veterans Affairs Medical Center \/ SHIRE PLC"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ SHIRE PLC","highestDevelopmentStatusID":"6","companyTruncated":"University of Wisconsin, Madison \/ SHIRE PLC"},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Unicycive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Unicycive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Unicycive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Lanthanum Carbonate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney ...

                          Product Name : Renazorb

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 28, 2022

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Under the terms of the asset purchase agreement, Unicycive has acquired global rights for Renazorb and all its trademark and associated patents, and Spectrum has received an equity interest in Unicycive along with milestone and royalty payments.

                          Product Name : Renazorb

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 14, 2020

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Unicycive Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 08, 2017

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Osaka University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Osaka University

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 11, 2014

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : Bayer AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 01, 2012

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 26, 2012

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 23, 2012

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Salem Veterans Affairs Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Salem Veterans Affairs Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 20, 2011

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of Wisconsin, Madison

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Wisconsin, Madison

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Lanthanum Carbonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Calciphylaxis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 04, 2011

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Fosrenol (Lanthanum Carbonate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperphosphatemia.

                          Product Name : Fosrenol

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 24, 2010

                          Lead Product(s) : Lanthanum Carbonate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : SHIRE PLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank